GRFS - グリフォルス (Grifols S.A.) グリフォルス

 GRFSのチャート


 GRFSの企業情報

symbol GRFS
会社名 Grifols SA Barcelona (グリフォルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   グリフォルスは、スペインのバイオ製薬会社。おもに血液派生物など治療製品の調達、製造、調合、販売を行う。血漿製剤、IV療法、経腸栄養剤、診断システムや医療素材を開発する。また病院の血液銀行と輸血センタ―向け製品を含む実験室分析用の診断製品の研究・開発を行う。さらに病院薬局、手術、栄養補給、輸液療法などに使用する非生物学的製品を取扱う。  Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.
本社所在地 Avinguda de la Generalitat 152-158 Parc de Negocis Can Sant Joan Sant Cugat del Valles Barcelona 08174 ESP
代表者氏名
代表者役職名
電話番号
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 15761人
url www.grifols.com
nasdaq_url https://www.nasdaq.com/symbol/grfs
adr_tso 140414347
EBITDA EBITDA ー
終値(lastsale) 20.48
時価総額(marketcap) 2875685826.56
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 GRFSのテクニカル分析


 GRFSのニュース

   Worldwide Blood Transfusion Devices Industry to 2026 - by Product, Blood Component, End-user and Region - ResearchAndMarkets.com  2021/12/17 14:10:00 Benzinga
The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreover, developments in terms of technology is expected to positively impact the growth of the market during the forecast period. Also, rise in number of blood related disorders is further expected to bolster the growth of market over the next few years.
   Grifols (NASDAQ:GRFS) Shares Gap Down to $10.86  2021/12/08 16:20:44 Dakota Financial News
Grifols, S.A. (NASDAQ:GRFS)s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $10.86, but opened at $10.41. Grifols shares last traded at $10.39, with a volume of 5,349 shares traded. A number of research firms recently commented on GRFS. Citigroup raised Grifols from a neutral rating to []
   Worldwide Bleeding Disorder Treatment Industry to 2026 - Featuring Amgen, Bayer AG and Grifols Among Others - ResearchAndMarkets.com  2021/12/07 20:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Bleeding Disorder Treatment Market (2021-2026) by Type, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Bleeding Disorder Treatment Market is estimated to be USD 13.5 Bn in 2021 and is expected to reach USD 18.6 Bn by 2026, growing at a CAGR of 10%. The factors driving the growth of the bleeding disorder treatment market a
   Crossmark Global Holdings Inc. Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)  2021/12/07 12:12:42 Transcript Daily
Crossmark Global Holdings Inc. purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 755,784 shares of the biotechnology companys stock, valued at approximately $11,042,000. Crossmark Global Holdings Inc. owned []
   Worldwide Blood Transfusion Devices Industry to 2026 - by Product, Blood Component, End-user and Region - ResearchAndMarkets.com  2021/12/17 14:10:00 Benzinga
The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreover, developments in terms of technology is expected to positively impact the growth of the market during the forecast period. Also, rise in number of blood related disorders is further expected to bolster the growth of market over the next few years.
   Grifols (NASDAQ:GRFS) Shares Gap Down to $10.86  2021/12/08 16:20:44 Dakota Financial News
Grifols, S.A. (NASDAQ:GRFS)s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $10.86, but opened at $10.41. Grifols shares last traded at $10.39, with a volume of 5,349 shares traded. A number of research firms recently commented on GRFS. Citigroup raised Grifols from a neutral rating to []
   Worldwide Bleeding Disorder Treatment Industry to 2026 - Featuring Amgen, Bayer AG and Grifols Among Others - ResearchAndMarkets.com  2021/12/07 20:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Bleeding Disorder Treatment Market (2021-2026) by Type, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Bleeding Disorder Treatment Market is estimated to be USD 13.5 Bn in 2021 and is expected to reach USD 18.6 Bn by 2026, growing at a CAGR of 10%. The factors driving the growth of the bleeding disorder treatment market a
   Crossmark Global Holdings Inc. Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)  2021/12/07 12:12:42 Transcript Daily
Crossmark Global Holdings Inc. purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 755,784 shares of the biotechnology companys stock, valued at approximately $11,042,000. Crossmark Global Holdings Inc. owned []
   Vacuum Blood Collection Bag Market Will Hit Big Revenues In Future | TERUMO, Wego, Fresenius, Grifols  2021/09/07 15:15:00 iCrowdNewswire
Global Vacuum Blood Collection Bag Market Status, Trends and COVID-19 Impact Report 2021, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, []
   Prothrombin Complex Market Significantly Stepping towards the Success Till 2027| Takeda, CSL, Grifols  2021/09/03 12:05:07 OpenPR
Coagulation factors II, VII, IX, and X, as well as proteins C and S, make up the human prothrombin complex. This medication is used to help the blood clot and stop bleeding. Because of its clinical advantage over fresh frozen
   Fully Automated Coagulometer Market Growth Powered with Latest Development Scenario| Erba Group, F Hoffmann-La Roche Ltd, Grifols SA, HemoSonics LLC, Abbott Laboratories  2021/09/02 09:18:16 OpenPR
This report studies the Fully Automated Coagulometer market in many aspects of the industry such as market size, market conditions, market trends and forecasts, and the report also provides brief information on competitors and specific growth opportunities with key market
   Global Compounding Chemotherapy Market Upgrade CAGR by +6%, by the end 2027| Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy  2021/09/01 12:30:03 OpenPR
Many technical advances and cutting-edge strategies have allowed pharmacies to respond to the needs of clinicians and boost the growth of the global compounding chemotherapy market. Furthermore, the increasing opioid scarcity s is expected to increase demand globally for compounding
   Covid-19 Impact on Plasma Fractionation Market to Witness Mounting Growth in Approaching Time | CSL, Grifols  2021/08/31 08:52:51 OpenPR
The report covers the present scenario and the growth prospects of the global Plasma Fractionation Market for year 2020 to 2027. This report also shows the most important factors that can lead to the acceleration and deterioration of market growth.

 関連キーワード  (― 米国株 グリフォルス GRFS Grifols S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)